REPH Insider Trading Activity and SEC Form 4 Filings
REPH insider trading summary
No open-market insider purchases or sales of Recro Pharma, Inc. (REPH) have been reported on SEC Form 4 in the past 12 months.
Latest REPH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 15, 2022 | J David Enloe Jr | Chief Executive Officer | Buy | $1K (512 @ $1.96) |
| Feb 15, 2022 | J David Enloe Jr | Chief Executive Officer | Buy | $1K (571 @ $1.77) |
| Jan 18, 2022 | J David Enloe Jr | Chief Executive Officer | Buy | $1K (602 @ $1.68) |
| Dec 21, 2021 | AWM Investment Company, Inc. | 10% Owner | Sell | $154K (99,398 @ $1.55) |
| Dec 16, 2021 | AWM Investment Company, Inc. | 10% Owner | Sell | $81K (50,000 @ $1.61) |
| Dec 15, 2021 | AWM Investment Company, Inc. | 10% Owner | Sell | $33K (20,000 @ $1.63) |
| Dec 15, 2021 | J David Enloe Jr | Chief Executive Officer | Buy | $993 (617 @ $1.61) |
| Dec 14, 2021 | AWM Investment Company, Inc. | 10% Owner | Sell | $17K (10,602 @ $1.57) |
| Dec 13, 2021 | AWM Investment Company, Inc. | 10% Owner | Sell | $33K (20,000 @ $1.63) |
| Nov 17, 2021 | James Charles Miller | Director | Buy | $2K (1,000 @ $1.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.